Bank of America
BDTX icon

Bank of America’s Black Diamond Therapeutics BDTX Stock Holding History

Bank of America’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$243K Buy
114,143
+63,040
+123% +$150K ﹤0.01% 5256
2025
Q4 		$124K Buy
51,103
+7,744
+18% +$27.4K ﹤0.01% 5540
2025
Q3 		$164K Buy
43,359
+7,972
+23% +$23.3K ﹤0.01% 6371
2025
Q2 		$87.8K Sell
35,387
-10,673
-23% -$20.6K ﹤0.01% 6579
2025
Q1 		$71.4K Sell
46,060
-28,659
-38% -$60.1K ﹤0.01% 6631
2024
Q4 		$160K Buy
74,719
+32,422
+77% +$92.9K ﹤0.01% 6213
2024
Q3 		$184K Buy
42,297
+23,410
+124% +$127K ﹤0.01% 6052
2024
Q2 		$88K Buy
18,887
+7,512
+66% +$40.3K ﹤0.01% 6305
2024
Q1 		$57.7K Sell
11,375
-45,559
-80% -$184K ﹤0.01% 6464
2023
Q4 		$160K Buy
56,934
+56,338
+9,453% +$132K ﹤0.01% 6194
2023
Q3 		$1.71K Buy
596
+584
+4,867% +$2.15K ﹤0.01% 7169
2023
Q2 		$60 Sell
12
-12,777
-100% -$26.1K ﹤0.01% 7453
2023
Q1 		$24.2K Sell
12,789
-25
-0.2% -$57 ﹤0.01% 6711
2022
Q4 		$23.1K Sell
12,814
-2,272
-15% -$4.09K ﹤0.01% 6689
2022
Q3 		$25K Sell
15,086
-34,639
-70% -$107K ﹤0.01% 6945
2022
Q2 		$122K Sell
49,725
-8,514
-15% -$19.8K ﹤0.01% 6372
2022
Q1 		$161K Sell
58,239
-886
-1% -$3.23K ﹤0.01% 6594
2021
Q4 		$316K Buy
59,125
+21,969
+59% +$153K ﹤0.01% 6206
2021
Q3 		$314K Sell
37,156
-9,676
-21% -$95.5K ﹤0.01% 5980
2021
Q2 		$570K Sell
46,832
-5,750
-11% -$114K ﹤0.01% 5314
2021
Q1 		$1.28M Sell
52,582
-5,115
-9% -$138K ﹤0.01% 4627
2020
Q4 		$1.85M Buy
57,697
+28,634
+99% +$941K ﹤0.01% 4013
2020
Q3 		$879K Buy
29,063
+17,182
+145% +$523K ﹤0.01% 4317
2020
Q2 		$501K Buy
11,881
+493
+4% +$18.1K ﹤0.01% 4620
2020
Q1 		$284K Buy
+11,388
New +$347K ﹤0.01% 4879

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bank of America's BDTX Position: Q1 2026 in Review

Bank of America increased its Black Diamond Therapeutics (BDTX) stake by 123% in Q1 2026, buying an estimated $150K and bringing the position to 114,143 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #5256.

Bank of America first reported a position in BDTX in Q1 2020 and has held it in 25 quarters since. The position peaked at $1.85M in Q4 2020. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Bank of America held 114,143 shares of Black Diamond Therapeutics worth $243K as of Q1 2026.
  • Bank of America bought 63,040 Black Diamond Therapeutics shares in Q1 2026, an estimated $150K.
  • Black Diamond Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5256 holding.
  • Bank of America first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • Bank of America's Black Diamond Therapeutics position peaked at $1.85M in Q4 2020.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.